- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia (AML)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1571KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 215KB)
Venetoclax – March 2021
Venetoclax: Tablet 100 mg; Venclexta®
Last updated
16 July 2021